NCT05285384CompletedNot Applicable
An Open-Label, Single-Arm Clinical Trial to Evaluate the Immunogenicity and Safety of a Booster Dose of an Adjuvanted Recombinant Spike Protein COVID-19 Vaccine (SpikoGen) in Kidney Transplant Recipients After Two Doses of Sinopharm COVID-19 Vaccine
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Cinnagen
- Enrollment
- 43
- Locations
- 1
- Primary Endpoint
- Percentage of participants with seroconversion for S1 binding IgG antibodies
Study Overview
Brief Summary
This is an open-label, single-arm clinical trial designed to evaluate the immunogenicity and safety of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen) produced by CinnaGen Co. in kidney transplant recipients after two doses of Sinopharm's inactivated virus vaccine. A total of 100 adult individuals receive a single dose of the SpikoGen COVID-19 vaccine at 1 to 3 months after the second dose of the Sinopharm COVID-19 vaccine. The injection is given in the deltoid muscle of the non-dominant arm. For immunogenicity assessments, blood samples will be collected one month after the booster injection. For safety assessments, all participants will be followed up for one month.
Study hypotheses include:
- A booster dose of the SpikoGen COVID-19 vaccine induces strong immunogenicity against SARS-CoV-2 in adult kidney transplant recipients who were fully vaccinated with Sinopharm COVID-19 vaccine.
- A booster dose of the SpikoGen COVID-19 vaccine is safe and tolerable in adult kidney transplant recipients who were fully vaccinated with Sinopharm COVID-19 vaccine.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female ≥18 years
- •Willing and able to comply with all study requirements, including scheduled visits, intervention, and laboratory tests
- •Kidney transplant recipients who had received two doses of Sinopharm vaccine after transplantation
- •Females must not be pregnant or breastfeeding
- •At least six months should have passed from the time of transplantation
- •Between 1 to 3 months should have passed from the second dose of Sinopharm vaccine
Exclusion Criteria
- •Subjects with signs of active SARS-CoV-2 infection at the screening visit
- •Subjects with a history of SARS-CoV-2 infection based on a positive PCR test result after the second dose of the primary vaccination
- •Subjects with an active CMV infection that requires treatment
- •Subjects who have received rituximab within 6 months prior to the screening visit
- •Subjects who have received intravenous immune globulin (IVIG) within 6 months prior to the screening visit
- •Subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products.
- •Subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study.
- •Subjects who have experienced transplant rejection within 30 days prior to the screening visit
- •Subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion.
Outcomes
Primary Outcomes
Percentage of participants with seroconversion for S1 binding IgG antibodies
Time Frame: One month after the booster dose
As measured by ELISA
Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies
Time Frame: One month after the booster dose
As measured by ELISA
Secondary Outcomes
- Geometric mean fold rise (GMFR) for SARS-CoV-2 neutralizing antibodies in subjects either with or without antibody responses at baseline(One month after the booster dose)
- Incidence of unsolicited adverse events(For one month after the booster dose)
- Change in T-cell IFN-γ secretion from baseline to one month after the booster dose(Baseline and one month after the booster dose)
- Incidence of solicited adverse events(For 7 days after the booster dose)
- Geometric mean fold rise (GMFR) for S1 binding IgG antibodies(One month after the booster dose)
- Geometric mean fold rise (GMFR) for S1 binding IgG antibodies in subjects either with or without antibody responses at baseline(One month after the booster dose)
- Percentage of participants with seroconversion for S1 binding IgG antibodies in subjects either with or without antibody responses at baseline(One month after the booster dose)
- Geometric mean fold rise (GMFR) for SARS-CoV-2 neutralizing antibodies(One month after the booster dose)
- Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies in subjects either with or without antibody responses at baseline(One month after the booster dose)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 2
The Immunogenicity and Safety of V-01-351/V-01D Bivalence VaccineCOVID-19 PandemicNCT05273528Livzon Pharmaceutical Group Inc.20
Unknown
Early Phase 1
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver CancerAdvanced Primary Liver CancerNCT05411757Shandong Public Health Clinical Center12
Unknown
Not Applicable
A Prospective, Open-label, Single-arm Clinical StudyRecurrent Glioblastoma MultiformeNCT04689087Sun Yat-sen University40
Recruiting
Phase 1
U87 CAR-T in Patients With Advanced Head and Neck TumorsNasopharynx CancerHead and Neck CancerNCT06614686Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd20
Recruiting
Phase 2
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionCarcinoma, HepatocellularNCT06454578Qilu Hospital of Shandong University30